Return to work following sickness absence due to infectious mononucleosis by Koopmans, P.C. et al.
  
 University of Groningen
Return to work following sickness absence due to infectious mononucleosis





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2010
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Koopmans, P. C., Bakhtali, R., Katan, A. A., Groothoff, J. W., & Roelen, C. A. (2010). Return to work
following sickness absence due to infectious mononucleosis. Occupational Medicine-Oxford, 60(4), 249-
254. https://doi.org/10.1093/occmed/kqq061
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Occupational Medicine 2010;60:249–254
doi:10.1093/occmed/kqq061
Return to work following sickness absence due to
infectious mononucleosis
P. C. Koopmans1,2, R. Bakhtali3, A. A. Katan4, J. W. Groothoff 2 and C. A. M. Roelen2,5
1ArboNed Occupational Health Services, Statistics, Paterswoldseweg 808, PO Box 141, 9700 AC Groningen, The Netherlands,
2Department of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30001,
9700 RB Groningen, The Netherlands, 3Maetis Occupational Health Services, Papiermolen 26–30, PO Box 405, 3990 GE Houten,
The Netherlands, 4ArboNed Occupational Health Services, Corporate Accounts, Zwarte Woud 10, PO Box 85091, 3508 AB
Utrecht, The Netherlands, 5ArboNed Occupational Health Services, Corporate Accounts, Dr Van Lookeren Campagneweg 2, PO
Box 158, 8000 AD Zwolle, The Netherlands.
Correspondence to: P. C. Koopmans, ArboNed Occupational Health Services, Statistics, PO Box 141, 9700 AC Groningen, The
Netherlands. Tel: 131 50 5244343; fax: 131 50 5276777; e-mail: petra.koopmans@arboned.nl
Background Epstein–Barr virus infectious mononucleosis among adults is notorious because of the prolonged
incapacitating fatigue it causes.
Aims To investigate the duration of sickness absence and return to work following infectious mononucleosis.
Methods Episodes of sickness absence due to infectious mononucleosis were selected from an occupational
health services register. The duration of sickness absence and return to work was assessed with
Kaplan–Meier survival analysis.
Results Two thousand one hundred and thirty-seven episodes of absence due to infectious mononucleosis had
a median duration of 91 days. Young employees (aged 15–24 years) had the highest return to work
rates. Women had longer sickness absence than men. Employees working in small companies were
absent longer than employees in large companies.
Conclusions Occupational physicians should advise gradual return to work, starting 4 weeks after the onset of the
illness, in order to prevent physical deconditioning and prolonged illness.
Key words Age differences; Epstein–Barr virus; gender differences; infectious mononucleosis; sick leave; sickness
absence; return to work.
Introduction
The Epstein–Barr virus is highly prevalent in adults all
over the world and spreads through intimate oral contact.
In Asia and the developing countries, children are
infected in the first years of their life, while primary infec-
tion is delayed in most developed countries [1]. In The
Netherlands, 50% of children .5 years of age and
90% of adults are reported to have had a subclinical in-
fection [2]. Symptomatic primary Epstein–Barr virus in-
fection is more commonly known as infectious
mononucleosis. It is an illness that afflicts adolescents
and young adults, as a febrile illness accompanied by
pharyngitis and lymphadenopathy [3].
Infectious mononucleosis should be suspected in
patients of 10–30 years of age who present with a sore
throat and severe fatigue. Mild neutrophil leucocytosis
is often present in the first few days, subsequently replaced
by characteristic mononuclear T-lymphocytes [4]. Positive
antibody titres are found in the serum in .80% of cases
after 1 week, and they remain positive for weeks. In-
fectious mononucleosis is a self-limiting disease, but
occasionally, it is complicated by a variety of acute neu-
rologic, haematological, hepatic, splenic, respiratory and/
or psychological complications [5,6].
More commonly, adults suffer from a distinct chronic
syndrome of fatigue, myalgia and need for sleep, which
may persist for several months after the acute infection
has resolved. Adults of working age, with clinically man-
ifest infectious mononucleosis, usually report sick be-
cause of the incapacitating fatigue, which limits their
daily and social activities. These symptoms are usually
thought to have a long duration (of months or even a year),
confirming the belief that it is necessary to be absent from
work for a long time. However, it has been reported that
poor physical functioning and less activity during conva-
lescence predict a prolonged state of the illness [7].
 The Author 2010. Published by Oxford University Press on behalf of the Society of Occupational Medicine.
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Little is known about the sickness absence and return
to work of employees with clinically manifest Epstein–
Barr virus infectious mononucleosis. Therefore, in this
study, we investigated the following:
i) the median duration of sickness absence due to infec-
tious mononucleosis,
ii) sociodemographic differences in the duration of sick-
ness absence due to infectious mononucleosis and
iii) the course of return to work following infectious
mononucleosis.
Methods
ArboNed Occupational Health Services registers the sick-
ness absence data of an average of 1 million Dutch employ-
ees working in a variety of companies and economic
sectors that are representative of the Dutch labour market.
In The Netherlands, employees report sick to their em-
ployer, who pays sickness benefits. The Dutch sickness ab-
sence legislation requires medical certification of sickness
by an occupational physician within the first 5 weeks of
sickness absence. The occupational physician enquires
about the sickness and documents the information in
the employee’s medical file, together with a diagnosis
based on codes of the International Classification of Dis-
eases (ICD) [8]. Occupational physicians use the ICD-10
code B27 for sickness absence due to serologically verified
infectious mononucleosis. We analysed all sickness ab-
sence episodes that were diagnosed as infectious mononu-
cleosis between January 2004 and June 2007. Return to
work can be partial or full. The period between the first
day of sickness absence and return to work to $50% of
contracted hours was regarded as the time until partial re-
turn to work and the period between the first day of sick-
ness absence and return to work to 100% of contracted
hours was defined as the time until full return to work.
The age of the employees was registered at the moment
when they reported sick, and four age groups were used
(15–24 years, 25–34 years, 35–44 years and 45–64 years).
Socio-economic status was determined according to
the postal code of the employee’s home address. The post-
al codes were linked to a status score on The Netherlands
Institute for Social Research tables, in which all postal
codes in The Netherlands are ranked on a scale from
1 to 4000, with 1 indicating the richest neighbourhood
and 4000 the poorest. For this study, we computed three
tertiles of these status scores, distinguishing between
high, medium and low socio-economic status. The com-
panies in which the employees worked were subdivided
into four size categories: employing ,75 employees,
75–499 employees, 500–4999 employees and $5000
employees.
The data were analysed in SPSS for Windows, version
15. Kaplan–Meier survival curves were computed to cal-
culate the median duration of sickness absence. When es-
timating the duration of episodes of sickness absence, it is
important to censor absences which have not ended be-
fore the end of the observation period or the dismissal
date [9] because we know that the date of recovery, if
any, is later than that date, but we do not know how much
later. Therefore, we censored absences that did not end
before 1 June 2007 (the end of the observation period)
or which ended in dismissal. A censored episode contrib-
utes to the duration of sickness absence but implies that
there was no recovery. Cox regression analysis was per-
formed to investigate the influence of the covariates
on the duration until return to work. Firstly, we analysed
the duration until partial return to work and secondly, the
duration until full return to work.
No approval from a medical ethics committee, or in-
formed consent, was required because the registered data
were analysed anonymously at group level.
Results
Between January 2004 and June 2007, we counted 2137
episodes of sickness absence certified as infectious mono-
nucleosis: 1069 in men and 1068 in women. The mean
age of the men was 30.9 (SD 5 9.5) years, and for the
women, it was 30.5 (SD 5 9.7) years. One hundred
and sixty episodes (15%) in the men and 201 episodes
(19%) in the women lasted for at least 6 months, and after
1 year, 20 men (2%) and 32 women (3%) were still absent
from work. Figure 1 shows that men and women in the
age group 15–24 years had a shorter duration of sickness
absence duration than employees in the older age groups
(logrank test: men P , 0.001 and women P , 0.001).
The duration of sickness absence had a positively
skewed distribution. Therefore, the median is preferred
as a central measure. The median duration of sickness ab-
sence was 91 days (95% CI 5 87–95 days) and was
shorter for men (median 86 days; 95% CI5 82–90 days)
than for women (median 98 days; 95% CI 5 92–104
days) (P , 0.001), as is shown in Table 1.
Table 2 shows the course of sickness absence due to
infectious mononucleosis from the start of the episode
until the end of the observation period. The median du-
ration until partial or full return to work in those who did
return to work was 45 days (95% CI 5 42–49 days) and
did not differ according to gender: 46 days (95% CI 5
42–49 days) for men and 44 days (95% CI5 40–49 days)
for women. The mean duration until partial or full return
to work was significantly (P, 0.05) longer for women.45
years than for younger women, while for men, the median
time until return to work did not differ significantly
between the age groups. Socio-economic status was not
associated with the duration until return to work.
Employees working in the largest companies returned to











Men and women ,25 years of age more often recov-
ered without partial return to work compared with
employees in the older age groups (logrank test: men
P , 0.001 and women P , 0.001). Employees in the
age groups of 25–34 years [hazard rate (HR) 5 1.39;
95% CI 5 1.21–1.59) and 35–44 years (HR 5 1.30;
95% CI 5 1.11–1.52) partially returned to work signifi-
cantly earlier than employees in the age group of 15–24
years but took longer until full return to work (HR 5
0.65; 95% CI 5 0.59–0.73 and HR 5 0.61; 95% CI 5
0.53–0.69, respectively), as is shown in Table 3.
For 1906 employees, we were able to count the number
of days of sickness absence in the year before sickness ab-
sence due to infectious mononucleosis, and we compared
this number with the number of days of sickness absence
during 12 months after full return to work. The average
number of sickness absence days in the previous year
was 13.4 (SD 5 26.7). This did not differ using the
paired t-test on the log-transformed number of days of
sickness absence from the number of days of sickness ab-
sence 1 year after full return to work (mean 5 12.5 days;
SD 5 29.7 days).
Figure 1. Full return to work following Epstein–Barr virus infectious mononucleosis according to age.
Table 1. The median duration (95% CI) of sickness absence due to infectious mononucleosis in men and women according to age, socio-
economic status and company size
Number of sickness absences Median duration of sickness absence in days (95% CI)
Men Women Total Men Women Total
Age (years)
15–24 358 385 743 70 (65–75) 85 (74–96) 73 (68–78)
25–34 363 392 755 91 (83–99) 110 (98–122) 102 (95–109)
35–44 255 195 450 104 (94–114) 107 (89–125) 106 (98–114)
$45 91 95 186 91 (71–111) 102 (72–132) 102 (90–114)
Socio-economic status
High 352 352 704 83 (75–91) 97 (89–105) 90 (84–96)
Medium 352 355 707 91 (83–99) 98 (87–109) 95 (88–102)
Low 353 351 704 82 (76–88) 105 (94–116) 91 (86–96)
Company size
,75 employees 372 334 706 91 (84–98) 112 (102–122) 100 (93–107)
75–499 employees 275 270 545 96 (84–108) 97 (86–108) 97 (89–105)
500–4999 employees 293 349 642 81 (74–88) 98 (87–109) 89 (83–95)
$5000 employees 121 109 230 65 (59–71) 70 (57–83) 68 (63–73)
Total 1069 1068 2137 86 (82–90) 98 (92–104) 91 (87–95)
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The median duration of sickness absence due to infec-
tious mononucleosis was 91 days and was longer for
women (98 days) than for men (86 days). The rates of
return to work were highest for young employees and
for employees working in large companies. It seems likely
that in large companies, there are more opportunities to
adjust the workload and the work tempo to the level of
physical functioning, in consultation with the supervisor
and colleagues. The number of sickness absence days in
the year before infectious mononucleosis did not differ
significantly from the number of days of sickness absence
in the year after return to work, suggesting that employees
Table 2. Partial return to work according to gender, age, socio-economic status and company size
No or ,50% partial




return to work, n (%)
Total, n
Men 15–24 years 42 (12) 146 (41) 170 (48) 358
Men 25–34 years 33 (9) 224 (62) 106 (29) 363
Men 35–44 years 15 (6) 181 (71) 59 (23) 255
Men $ 45 years 2 (2) 58 (64) 31 (34) 91
Women 15–24 years 49 (13) 189 (49) 147 (38) 385
Women 25–34 years 36 (9) 290 (74) 66 (17) 392
Women 35–44 years 27 (14) 120 (62) 48 (25) 195
Women $ 45 years 3 (3) 59 (62) 33 (35) 95
Company size
,75 employees 100 (14) 379 (54) 227 (32) 706
75–499 employees 39 (7) 374 (69) 132 (24) 545
500–4999 employees 44 (7) 386 (60) 212 (33) 642
$5000 employees 22 (10) 123 (54) 85 (37) 230
Socio-economic status
High 70 (10) 434 (62) 200 (28) 704
Medium 74 (11) 410 (58) 223 (32) 707
Low 61 (9) 413 (59) 230 (33) 704
Total 208 (10) 1268 (59) 661 (31) 2137
aPartial return to work 5 return to work to $50% of contracted hours.
Table 3. Cox regression of duration until partial and full return to work
Partial return to worka Full return to work
HR (95% CI) HR (95% CI)
Men (reference) 1.00 1.00
Women 1.04 (0.93–1.16) 0.81 (0.74–0.89)**
Age
15–24 years (reference) 1.00 1.00
25–34 years 1.39 (1.21–1.59)** 0.65 (0.59–0.73)**
35–44 years 1.30 (1.11–1.52)** 0.61 (0.53–0.69)**





75–499 employees 1.45 (1.25–1.67)** 1.18 (1.04–1.33)**
500–4999 employees 1.29 (1.12–1.49)** 1.20 (1.07–1.34)**
$5000 employees 1.31 (1.07–1.61)** 1.51 (1.28–1.77)**
Socio-economic status
High 1.02 (0.89–1.17) 1.01 (0.91–1.13)
Medium 0.91 (0.79–1.04) 0.92 (0.82–1.03)
Low (reference) 1.00 1.00
The table shows HR and their 95% CI. A HR .1 indicates a shorter duration until (partial) return to work, whereas a HR ,1 reflects a longer duration; *P , 0.05 and
**P , 0.01.
aPartial return to work 5 return to work to $50% of contracted hours.
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return to normal working capacity after full return to
work.
For this study, we selected sickness absence episodes
certified as infectious mononucleosis by an occupational
physician. The diagnostic codes documented by the occu-
pational physicians were based on serologically verified in-
fectious mononucleosis, implying that the diagnoses had
a high specificity. This may have over-estimated the dura-
tion of sickness absence because patients with mild-to-
moderate malaise and fever may remain unrecognized
in primary care or they sometimes continue to work de-
spite their moderate illness. We had no knowledge about
comorbidity or whether complications occurred over time.
Psychiatric disorders, and especially mood disorders, are
prevalent in patients suffering infectious mononucleosis,
particularly in the first 6 months of the illness [10,11].
Epstein–Barr virus infectious mononucleosis has a dif-
ferent course in adults than in adolescents. Adults mainly
suffer from a fever, often with liver abnormalities [12],
and delayed convalescence is not uncommon. Buchwald
et al. [13] reported that 12% of adults failed to recover 6
months after acute glandular fever. White et al. [10] re-
ported that 40% of patients with infectious mononucle-
osis were still severely fatigued after 6 months and 22%
suffered hypersomnia. Our results showed that 50%
of the employees returned to work 3 months after the di-
agnosis and 80% returned to work after 6 months. Sick-
ness absence lasted for .1 year in 2–3% of the adults.
Lambore et al. [14] found that 6% of adults with chronic
symptoms of infectious mononucleosis reported that their
tiredness and daytime sleepiness persisted for .1 year.
Earlier research has shown that rest is the most com-
mon advice given by general practitioners to patients with
infectious mononucleosis [15]. However, poor physical
functioning plays a key role in causing prolonged symp-
toms following acute infectious mononucleosis. Candy
et al. [7] reported that restriction of activities in the acute
phase is associated with a poorer outcome, in terms of
longer work incapacity. In the literature, gradual return
to competition is recommended for sportsmen with no
spleen enlargement 4 weeks after the onset of illness
[16,17]. In occupational medicine practice, abdominal
ultrasound scanning is often not available to demonstrate
hepatomegaly or splenomegaly; however, these complica-
tions mostly appear in the first 4 weeks of illness [16].
Therefore, it should be feasible for employees to gradually
return to work 4 weeks after the onset of sickness absence
due to infectious mononucleosis. However, our results
show that return to work takes almost twice as long be-
cause the median duration until partial or full return to
work was 45 days (95% CI 5 42–49 days) for those
who did return to work.
The World Health Organization International Classi-
fication of Functioning, Disability, and Health explains
how disease and disability are related [18]. Diseases or
disorders affect body structure and function, impair activ-
ities and restrict participation. Whether or not this leads
to disability depends on conditional factors of environ-
mental origin (such as workload) and of personal origin
(such as personal ideas about the illness). In assisting a pa-
tient to recover from infectious mononucleosis, the occu-
pational physician has three opportunities to stimulate
return to work. The first opportunity is to include daily
activities and return to work in the treatment, instead
of advising rest. Second, special arrangements, such as
gradual return to work, reduced workload or modified
work, may facilitate the return to work of employees. Sup-
port from close relatives, attending physicians and col-
leagues and a supportive work environment contribute
to the self-confidence of employees in returning to work.
Third, attention must be paid to changing disability cog-
nitions, particularly unreal beliefs and views about pro-
longed disability following infectious mononucleosis. It
has recently been reported that patients with infectious
mononucleosis who were advised to pursue activities in
a psycho-educational intervention recovered faster than
patients with restricted activity [15].
We conclude that in our study population, the duration
until return to work following infectious mononucleosis
exceeded the recommendations and the duration
reported in a population of sportsmen [16,17]. General
practitioners and occupational physicians should avoid
advising rest, in order to prevent prolonged fatigue and
failure to recover. If there are no complications, it is safe
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